Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cenicriviroc - Tobira Therapeutics

Drug Profile

Cenicriviroc - Tobira Therapeutics

Alternative Names: Cenicriviroc mesylate; CVC; TAK-652; TBR-652

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Institute for Health Research; Takeda
  • Developer Allergan; Dong-A ST; Imperial College of Science, Technology and Medicine; National Institute for Health Research; Novartis; Tobira Therapeutics; University of Hawaii
  • Class Amides; Antifibrotics; Antineoplastics; Antiretrovirals; Imidazoles; Small molecules
  • Mechanism of Action CCR2 receptor antagonists; CCR5 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-alcoholic steatohepatitis
  • Phase II Cognition disorders; HIV-1 infections; Non-alcoholic fatty liver disease; Primary sclerosing cholangitis
  • Phase I Liver disorders
  • Preclinical Cholestasis; Diabetic nephropathies
  • No development reported Cancer; Graft-versus-host disease

Most Recent Events

  • 11 Sep 2018 Phase-II clinical trials in Non-alcoholic steatohepatitis (Combination therapy) in Spain, USA, Latvia, Czech Republic (PO) (EudraCT2017-004208-24) (NCT03517540)
  • 11 Sep 2018 Phase-II clinical trials in Non-alcoholic steatohepatitis in Czech Republic, Latvia (PO) (EudraCT2017-004208-24)
  • 11 Sep 2018 Allergan and Novartis initiates enrolment in the TANDEM phase II trial for Non-alcoholic Steatohepatitis in Spain and USA (EudraCT2017-004208-24) (NCT03517540)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top